Estée Lauder
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Largest pure-play prestige beauty conglomerate (La Mer, Clinique, Estée Lauder, MAC, Tom Ford, Jo Malone) with deep brand portfolio — moat real and less strained than a year ago after four consecutive organic-growth quarters, Mainland China/Japan/Korea share gains, and Jo Malone London plus TOM FORD joining the billion-dollar-brand list. Makeup is still the soft spot (FY26 sales virtually flat) and Korean/Chinese competitive pressure has not gone away.
Estée Lauder's moat is a portfolio of prestige beauty brands with global distribution scale — durable in theory, currently repairing:
- Prestige Brand Heritage: La Mer, Estée Lauder, Tom Ford, Jo Malone, MAC, Clinique remain one of the deepest prestige portfolios globally. Jo Malone London and TOM FORD crossed into billion-dollar brands in FY26, taking the list to six. Brand heritage and pricing power persist — La Mer still holds $300+ price points; fragrance (Le Labo, TOM FORD, KILIAN PARIS) delivered double-digit organic growth and led the FY26 recovery.
- Global Distribution Footprint: Distribution scale across department stores, travel retail, specialty (Sephora, Ulta), Amazon (13 brands / 11 markets) and TikTok Shop (12 brands / 9 markets) is a competitive advantage smaller prestige players cannot match. FY26 posted net sales growth in every geographic region; Mainland China, Japan and Korea all took prestige share in Q4, and M·A·C launched in select U.S. Sephora doors.
- M&A and Brand Building Track Record: EL has a long track record of acquiring and scaling prestige brands (Tom Ford, Jo Malone, Bobbi Brown, La Mer, Deciem/The Ordinary). Capital allocation is turning more constructive — remaining Forest Essentials interest (subject to approval), minority stakes in XINÚ and 111Skin — though makeup brands (Bobbi Brown, Too Faced) still need work.
Moat Verdict
Estée Lauder's moat is brand + distribution scale, AI-neutral and less strained after four consecutive organic-growth quarters, Q4 share gains in China/Korea/Japan, and two new billion-dollar brands. The thesis is Beauty Reimagined / PRGP execution plus sustained China recovery — FY26 confirmed the direction (organic +3%, OM 11.2%, FY27 OM raised). Makeup remaining flat is the unfinished half. Valuation offers turnaround optionality with less execution risk than in May, after the stock paid up on the print.
43.7 resilient · 55.0 vulnerable · 80/20 = 46.0 · = 46
Open a moat to read its note.
consumer brand.
N/A.
N/A.
Brand-building and prestige-marketing talent is real but increasingly available across the industry.
Multi-brand portfolio gives meaningful retailer-shelf and travel-retail negotiating power that single-brand competitors cannot match; Jo Malone and TOM FORD joining the billion-dollar list deepens that shelf power.
Loyalty + DTC data exists but is fragmented across brands and not deeply monetised.
beauty regulation is broadly applicable to all market participants.
N/A.
No subscription; embedment is brand affinity and habit, easily disrupted by Korean / Chinese / indie competition.
N/A.
Not a source of durability for this business: no structural unit-cost gap versus rivals that the other pillars do not already capture.
Prestige brands (Estée Lauder, La Mer, Clinique, TOM FORD, Jo Malone) still carry premium pricing, and two new billion-dollar brands show the portfolio can build, but K-beauty and indie brands have eroded share and the premium is being re-earned.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Largest pure-play prestige beauty conglomerate (La Mer, Clinique, Estée Lauder, MAC, Tom Ford, Jo Malone) with deep brand portfolio — moat real and less strained than a year ago after four consecutive organic-growth quarters, Mainland China/Japan/Korea share gains, and Jo Malone London plus TOM FORD joining the billion-dollar-brand list. Makeup is still the soft spot (FY26 sales virtually flat) and Korean/Chinese competitive pressure has not gone away.
Growth Score
FY26 organic sales +3% (as-reported +5% to $15.0B) with Q4 organic +5% — the fourth consecutive growth quarter — and adj. operating margin 11.2% (from 8.0%), beating the raised 10.7–11.0% guide. Adj. EPS $2.51 vs $2.35–$2.45 guide. FY27: organic +3–5%, adj. OM raised to 12.7–13.5% from the May prelim of 12.5–13.0%, adj. EPS $3.10–$3.35. Fragrance +10% led; makeup still flat.
Valuation Score
At ~$98 after the Aug 19 print (+12% on the day) EL sits ~11% below the $110 base and ~51% above the $65 bear — still ~65% below 2021 highs. On FY26 adj. EPS ($2.51) the stock screens expensive (~39×), but on FY27 adj. EPS ($3.10–$3.35) it is ~30×, compressing toward the mid-20s on a FY28 normalised mid-cycle EPS path if Beauty Reimagined and PRGP keep delivering.
The Prestige Brand Portfolio Moat
Estée Lauder's moat is a portfolio of prestige beauty brands with global distribution scale — durable in theory, currently repairing:
- Prestige Brand Heritage: La Mer, Estée Lauder, Tom Ford, Jo Malone, MAC, Clinique remain one of the deepest prestige portfolios globally. Jo Malone London and TOM FORD crossed into billion-dollar brands in FY26, taking the list to six. Brand heritage and pricing power persist — La Mer still holds $300+ price points; fragrance (Le Labo, TOM FORD, KILIAN PARIS) delivered double-digit organic growth and led the FY26 recovery.
- Global Distribution Footprint: Distribution scale across department stores, travel retail, specialty (Sephora, Ulta), Amazon (13 brands / 11 markets) and TikTok Shop (12 brands / 9 markets) is a competitive advantage smaller prestige players cannot match. FY26 posted net sales growth in every geographic region; Mainland China, Japan and Korea all took prestige share in Q4, and M·A·C launched in select U.S. Sephora doors.
- M&A and Brand Building Track Record: EL has a long track record of acquiring and scaling prestige brands (Tom Ford, Jo Malone, Bobbi Brown, La Mer, Deciem/The Ordinary). Capital allocation is turning more constructive — remaining Forest Essentials interest (subject to approval), minority stakes in XINÚ and 111Skin — though makeup brands (Bobbi Brown, Too Faced) still need work.
Moat Verdict
Estée Lauder's moat is brand + distribution scale, AI-neutral and less strained after four consecutive organic-growth quarters, Q4 share gains in China/Korea/Japan, and two new billion-dollar brands. The thesis is Beauty Reimagined / PRGP execution plus sustained China recovery — FY26 confirmed the direction (organic +3%, OM 11.2%, FY27 OM raised). Makeup remaining flat is the unfinished half. Valuation offers turnaround optionality with less execution risk than in May, after the stock paid up on the print.
43.7 resilient · 55.0 vulnerable · 80/20 = 46.0 · = 46
Open a moat to read its note.
consumer brand.
N/A.
N/A.
Brand-building and prestige-marketing talent is real but increasingly available across the industry.
Multi-brand portfolio gives meaningful retailer-shelf and travel-retail negotiating power that single-brand competitors cannot match; Jo Malone and TOM FORD joining the billion-dollar list deepens that shelf power.
Loyalty + DTC data exists but is fragmented across brands and not deeply monetised.
beauty regulation is broadly applicable to all market participants.
N/A.
No subscription; embedment is brand affinity and habit, easily disrupted by Korean / Chinese / indie competition.
N/A.
Not a source of durability for this business: no structural unit-cost gap versus rivals that the other pillars do not already capture.
Prestige brands (Estée Lauder, La Mer, Clinique, TOM FORD, Jo Malone) still carry premium pricing, and two new billion-dollar brands show the portfolio can build, but K-beauty and indie brands have eroded share and the premium is being re-earned.
Growth Analysis
Growth Drivers
Key Risk
If Mainland China and travel-retail momentum stalls after four growth quarters — or makeup share losses to Korean/Chinese prestige brands accelerate — FY27's 3–5% organic / 12.7–13.5% OM view slips and the multiple stays pinned to trough-to-mid-cycle EPS rather than a durable recovery.
Score Derivation
61.3 base + 1.3 trajectory + 4 margin − 5 risk = 62
Base 61 (3–6% CAGR mid-band) + 2.7 trajectory (PRGP and brand portfolio accelerating; travel-retail/regional mix stable) + 4 margin expansion (OM 8.0% → 11.2% FY26, guided 12.7–13.5% FY27) − 5 China/competitive residual risk = 63. Four consecutive organic-growth quarters and Q4 share gains in China/Korea/Japan are now observed, so they sit in the drivers rather than in severity; remaining downside is whether makeup stays flat and the recovery holds. Re-checked 2026-09-25: "PRGP Cost Program" is a margin or profit line, not a revenue driver (margin is scored once, in marginTrend), so it is held stable. Trajectory 2.7 → 1.3; growth score = 62.
Price Scenarios (12–24 Months)
Valuation Multiples
| Forward P/E (FY26 adj.) | ~39× |
| Forward P/E (FY27 adj.) | ~30× |
| Price / Sales (FY26) | ~2.4× |
| Dividend Yield | ~1.4% |
| FCF Yield | ~3.7% |
The print confirmed the turnaround the May/August preview was waiting on — and the stock paid up 12% for it. Spot now prices a partial recovery (four growth quarters, OM 11.2%) but not full mid-cycle margins. Margin of safety exists versus prior-cycle highs, not versus a clean mid-cycle multiple on today's EPS.
Approximate figures as of August 19, 2026.
Where We Are vs Targets
Loading live price…
China/travel-retail bounce fades, Korean/Chinese brands keep taking makeup share, PRGP savings disappoint, and the multiple stays ~20× on sub-$3.50 EPS.
- Mainland China retail growth reverts to flat/negative through 2027
- Travel retail stalls after the FY26 regional bounce; airport-channel transitions linger
- PRGP run-rate benefits slip past FY27; adj. OM stuck below 12%
FY27 delivers company-like +3–5% organic and ~13% adj. OM; FY28 EPS reaches ~$4.50–$5.00 and the multiple holds ~22–24× as the turnaround is treated as durable.
- Regional growth holds; China/Korea/Japan share gains persist even if the rate slows
- Operating margin recovers to ~13% in FY27 on PRGP run-rate as guided
- Fragrance + skincare offset makeup; Clinique/Tom Ford/La Mer/Jo Malone carry mix
Full Chinese consumer and travel-retail recovery plus successful PRGP execution drives FY28 EPS to $6.50+ and a quality re-rate toward ~23×.
- Chinese consumer recovery accelerates in 2026–27; travel retail remixes toward prior peak contribution
- Operating margin recovers toward 15–16% by FY29
- M&A reignites with bolt-on Asian and indie prestige brands once the balance sheet flexes